Update shared on27 Oct 2025
Fair value Increased 8.62%Analysts have raised their price target for Medistim from NOK 290 to NOK 315, citing improved revenue growth projections and higher expected profit margins.
What's in the News
- Medistim completed the repurchase of 189,224 shares, representing 1.04% of its outstanding shares, for a total of NOK 12.5 million. This was part of the buyback program announced in March 2025 (Key Developments).
- Between April 1 and June 30, 2025, the company repurchased 146,681 shares, which accounts for 0.8% of its shares and was valued at NOK 4.59 million (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has increased from NOK 290 to NOK 315, reflecting a higher fair value estimate.
- Discount Rate has risen slightly from 6.73% to 6.77%, indicating a modest adjustment in risk assumptions.
- Revenue Growth projections have improved from 8.85% to 9.69%.
- Net Profit Margin forecast has increased from 22.28% to 23.22%.
- Future P/E multiple estimate has decreased slightly from 35.15x to 34.01x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.